Pathological Tumor and Lymph Node Responses After Neoadjuvant Immunochemotherapy in Initially-unresectable NSCLC

Guangdong Provincial People's Hospital (Guangdong Provincial Academy of Medical Sciences)

Status: Completed

Conditions: Chemotherapy; Immunotherapy; Non Small Cell Lung Cancer; Tumour, Residual

Treatments: Drug: Timing of drug administration

Study type: Observational

Funder types: Other

Identifiers

NCT05637580

LUNGTN

Details and patient eligibility

About

This is a real-world study with the largest sample size investigating the pathological tumor and lymph node responses to neoadjuvant immunochemotherapy in non-small cell lung cancer to date. Patients with initially unresectable NSCLC underwent immunochemotherapy and response to treatment was assessed after every two treatment cycles. Clinicopathologic features of patients including epidemiological data, clinical manifestations, operation strategies, pathological findings, and prognostic information were recorded and evaluated.

Enrollment: 110 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with stage III NSCLC who received neoadjuvant immunochemotherapy.
• early-stage NSCLC patients who were initially unresectable.
• 18 years of age or older.
• Karnofsky performance status (KPS) score of 100 or 90.

Exclusion criteria

• Patients with stage IV NSCLC
• Patients with known ALK translocations or EGFR mutations.
• Karnofsky performance status (KPS) score <90.

Trial design

110 participants in 2 patient groups

combined well responder

Description:

Both primary tumor and nodal response achieve major pathological response (MPR).

Treatment:

Drug: Timing of drug administration

poor responder

Description:

Primary tumor or/and nodal response can not achieve MPR.

Treatment:

Drug: Timing of drug administration